Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This are the news from Australia !
Scientists hope for better treatment options for Covid-19 patients.
With help of a method based on the Crispr gene scissors, Australian researchers have succeeded in stopping the SARS-CoV-2 coronavirus from multiplying in an infected cell. This is the result of a study published on Tuesday in the journal Nature Communications.
In the long term, according to Sharon Lewin's team from the Australian Peter Doherty Institute for Infection and Immunity, better treatment of Covid 19 patients could be possible.
The scientists used a form of Crispr Gene Scissors, with which parts of the genetic material can be cut out and replaced. For their experiments under laboratory conditions, they used the enzyme Crispr / Cas13b. This binds certain RNA sequences of the coronavirus and switches off the part that the virus needs to replicate in the infected cell.
"As soon as the virus is recognized, the Crispr enzyme is activated and cuts the virus," said Lewin. According to her, the method works both for parts of the virus "that are very stable and do not change" and for those "that are highly changeable". The technology has also proven to be effective with virus variants such as the alpha mutant. So far, however, the method has only been tested under laboratory conditions. The team now hopes to be able to try them out on animals.
So far, there are only a few and only partially effective treatment options for Covid-19. "We still need better treatments for people who are in hospital for Covid-19," said Lewin. "Our current options here are limited and at best reduce the risk of death by 30 percent."
The use of the Crispr technique in general medicine is probably "years, not months," away, said Lewin. Nevertheless, it could prove useful in the fight against Corona.
According to the researcher, the ideal treatment would be a simple antiviral drug that is taken as soon as possible after a positive corona test to prevent a severe course. According to Lewin, the researchers hope that their findings will contribute to the development of such a cheap, oral drug.
I am constantly following your posts and also read about your suffering.
What interests me is completely private:
What is your weight and how tall are you? Were you a good athlete in your youth? How is your blood pressure now?
May be, I'm able to help you!
IMO it's the problem only !
Funny News (but not for RLFTF)
NEW YORK TIMES (July 8, 2021 2:23 PM EST)
Isn't that all of them?
About 20% of individuals with Corona Virus disease (COVID-19) experience more severe disease characterized by significant respiratory symptoms including acute respiratory distress syndrome (ARDS). ARDS is a known lethal complication due to its low blood oxygenation levels and may result in organ failure. Until now, there are no specific vaccines or therapeutic drugs targeting SARS-CoV-2, alternative therapeutic interventions are needed to prevent and ameliorate respiratory conditions associated with COVID-19 to effectively reduce mortality and prevent ICU admissions.
Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS.
Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it prevents N-methyl-D-aspartate (NMDA)-induced caspase-3 activation, inhibits IL-6 and TNFa production and protects against HCl-induced pulmonary edema. Further, in animal model systems of lung injury in mice, rats, guinea pigs, sheep, swine and dogs, Aviptadil was shown to restore barrier function at the endothelial/alveolar interface and to protect the lung and other organs from failure. In Europe, Aviptadil is approved for human use and has been shown to be safe in phase II trials for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction as well as in a phase I trial in ARDS in the past two decades.
Read more here:
https://clinicaltrials.gov/ct2/show/NCT04536350?term=Aviptadil&draw=2&rank=2
News from Advita
advita-lifescience.com/newsroom/
The number of COVID-19 cases continues to decline, but the end of the pandemic is not in sight. The wish was expressed by various clinicians in Europe to participate in the COVID-19 study with inhaled Aviptadil under the direction of Prof. Leuppi. The EudraCT No. was communicated to us yesterday. This allows every hospital within the EU to participate.
Corruption is spreading more and more !
.... and we act like lemmings.
POTUS in Cornwall! Boris Johnson's guest. There is talk of world politics. About pandemic also.
Biden said, among other things: "... in terms of pandemic it is a fight for life or death!"
I agree with him!
But doesn't the FDA know that yet?
Vanilla....
....a completely unnecessary statement !
There are PR's in Europe! But they have nothing to do with NRX!
@Ria2 - maybe! Last two weeks I received a lot of emails from them.
I am invested in RLF Switzerland (SIX) and receive the latest news by email 2-3 times a week. I don't know what you mean vanilla? I am well informed!
So one could be mistaken a long time before !
"Your numbers are not correct and it’s the misinformation like this that is causing the panic in the uneducated."
Pegs1
I just signed up again to give you a few informations that most people here don't even know (and are probably not interested in):
1) Dated June 25, 2020
https://www.nejm.org/doi/10.1056/NEJMc2000343
2) Scientist at the University Medical Center Freiburg, Freiburg, Germany
Bjorn C. Frye, M.D.
Frank Meiss, M.D.
Dagmar von Bubnoff, M.D.
Gernot Zissel, Ph.D.
Joachim Müller-Quernheim, M.D.
who founded ADVITA and celebrate a big succses at the moment!
3) ABOUT ADVITA LIFESCIENCE GMBH
AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and strategies to improve the therapy and diagnosis of rare lung diseases.
.... and now I'm unloged again !
Have a great day
Claus from Europe
NO !!! Why ?
Vanilla Fitbit & Tiger Money
Your impatience is fantastic!
You're right about some things, so you have not to repeat this every day.
As I always say: Time will tell!
But I don't mean: TODAY
Stay patient my friends!
In German there is a saying: "The jug goes as long to the well, until it breaks."
Relief will be successful, but certainly not with NeuroRX!
My questions are very simple!
Why did BRPA's PPS increase by 380% in December 2020 and 600% in February 2021?
Has BRPA already invested all of its money in Zyesami step by step while Dr.JJ is not even CEO of the new legal venture (which doesn't even exist yet!)?
Wasn't there a similar situation at the end of July 2020?
.... but that was shortly before patent's success report. The money has been invested by GEM back then.
Today BRPA is 5.83% down. What's the matter?
Time will tell!
Let's see if it's really like that.
Time will tell !
I just planned to post the issues between March 2020 and today.
I rather wont do it !
I don't want to doubt your opinion.
pegs1 - please do me a favor!
Are you able to tell me who is the registered owner of the trademarks ZyesamiTM and Rlf-100TM?
But answer if you know for sure only!
In this study:
I totally agree with you!
IMO there was a loophole in the cooperation agreement and thus they provoked an "OUT" to get rid of Relief. Relief missed the opportunity to take legal action immediately, but they will win anyway. I would not trust the amicable agreement announced by NeuroRX. They just try to delay everything.
not yet, but soon !
Who or what is NeuroRX?
Let's NeuroRX answer that for itself.
The company is also featured in their monthly PR.
The evolution of a small pharmaceutical company:
About NeuroRX (December 7, 2021)
NeuroRX has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop a drug for suicidal bipolar depression called NRX-101, currently in Phase 3 trials. Its work with RLF-100 (licensed from Relief Therapeutics) was originally considered for treatment of erectile dysfunction. The U.S. and Israeli-based biotech NeuroRX owns the rights to the drug in the United States. The U.S. FDA granted a fest-track designation to RLF-100 for treatment of respiratory distress in COVID-19. By September, 2020 NeuroRX submitted a request for Emergency Use Authorization in the USA for its use in patients in intensive care.
About NeuroRX (April 7, 2021)
NeuroRX draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRX has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division. NeuroRX recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp (NASDAQ:BRPA) (“BRPA”), and intends to apply for listing on the NASDAQ under the proposed symbol “NRXP”.
Reported May 1, 2021
Strategically Situated Georgia Links Deal with NeuroRX for Access to ZYESAMI: Lawsuits Most Certainly Imminent
Unfortunately, nowhere is stated where the funds for the development of various drugs came from. Larger investors may also be involved, but IMO they must have made the money selflessly available. It's a miracle that something like this still exists today.
It was you answer: "brutal" .....
..... but Vanilla said nearly the same (:
Penny !
I did it for two times and at the end I missed millions.
Here a reminder (post# 38396) what can happen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163229847
Don't be careless, stay calm !!
This is the most positive answer to all of my posts (some have been deleted already). You can't better describe RELIEF's future sucess.
Time will tell us all !
Thank you so much !!
Just think about it for yourself:
NeuroRx is a small private US pharmaceutical company that discovered the basis for a gold mine by the use of Avitadil. Based on a cooperation agreement, NeuroRx agreed to conduct a clinical trial to achieve an EUA by the FDA, which will be funded by Relief, which also holds the patent for Aviptadil. The success seems to be immeasurable. Even before the first trial is completed, NeuroRx begins to initiate another study and is obviously trying to steal its way out of the cooperation agreement.
Regardless of the agreements contents, NeuroRx generates and charges millions in costs that Relief doesnt want to pay without an examination. Due to the foregoing said, NeuroRx derived a breach of the cooperation agreement and has found a new investor in Big Rock Partners Acquisition Corp (BRPA) who intends to issue on the stock exchange together with NeuroRx in the second half of 2021.
While Relief has already invested hundreds of millions in the RLF-100 project, Big Rock Partners Acquisition Corp will likely finance the new Zyesami project with just as much effort. However, after the trials successfull completition and before request an approval, BRPA is one of many investors. They dont have a patent. They have a contract only and nothing else.
... and now an ambitious, successful but very greedy CEO takes the stage. The expected profit must be shared. There is a contract with Relief with obligation of 50% payment, otherwise there are no licenses for Aviptadil, and a large part of the profit will also be due to BRPA, because BRPA has financed the success also
..... and a small proportion remains only of the Goldmine, existing at the beginning.
So what to do as an equally successful CEO to come to terms? What a dilemma ! The contract with BRPA can be terminated only prematurely after BRPA is guilty of a breach of contract that justifies this termination. But BRPA doesnt do it of course, but NeuroRx. BRPA will sue for the funds made available so far, but after an application is only applied for after this embarrassing situation, NeuroRx is able to pay the claims made on them from the postage.
....and BRPA is, where they were at the beginning !
Your criticism is legitimate and true! But you should tell the culprit by name:
It's Dr. Javitt, CEO of NEURORX who is constantly trying to override the cooperation agreement concluded with Relief. This agreement was funded primarily by Relief and is expected to be fulfilled with EUA by the FDA. In one of the last statements made by NEUROX Dr. Javit's shows what he is thinking about:
That's how I see it too ! The performance of Dr.JJ for his honor, but the way he deals with it you may call him as a gangster. His statement on Twitter only:
Where is no plaintiff, there is also no judge!
But I cannot imagine that RELIEF will remain inactive here. It will soon turn out !!
Does it matter ?
Here is the answer (I issued x-times before)
Dr.JJ:
"As soon as the regulatory files are completed for transmission to FDA, they will be able to be available to European regulators as well. Anyone who thinks we would endanger patients, simply because of the financial behavior of a collaborator is sadly mistaken."
abc4.com:
This story is too important to turn a blind eye to. Please, get this story covered and reported.
The trial’s results are readily available for review online…all you have to do is search for it.
In this interview on 04/07/21 (from 42:00), Dr JJ did not mention Aviptadil, RLF-100 or Zyesami.
He always talked about the drug. He also did not mention the cooperation agreement with Relief Therapeutics
.... but asked when this drug will be available to the public, he evaded.
IMO it's like I mentioned earlier: Dr JJ gave himself an advance and thinks he's the winner. But the receipt is only issued at the very end !!